Principal Investigator: Sarah Michel (CTP contact: Vyomesh Patel)
Funding Mechanism: Centers of Excellence in Regulatory Science and Innovation Grant (CERSI)
ID number: 3U01FD005946-03W1
Award Date: 9/1/2018
Institution: University of Maryland School of Pharmacy
This project will use the electronic nicotine delivery systems (ENDS) aerosolization machine previously developed by the research team to expose normal human cells to complex ENDS aerosol mixtures and determine the physiological and pathological effects from exposure. Study aims are: (1) to determine the effects of ENDS aerosol on cells of the oral cavity and upper respiratory tract, and (2) to identify the constituents of e-liquids, hardware and aerosol to which ENDS users are exposed. In this study, five pre-filled ENDS and two cartomizers and their associated e-liquid formulations will be aerosolized and effects on cells will be assessed (via proteomics and in vitro cell biology assays of specific biological pathways by immunoblotting, cytokine quantitation and metallomics) against appropriate controls. Researchers will also analyze ENDS hardware, e-liquids (including color and ingredients), and the constituents of the complex aerosol for each ENDS category evaluated. All data collected will be compiled into a database that may help to inform the regulatory decision-making process. Project findings may inform future regulatory activities related to ENDS.